QURE - Why Are UniQure Shares Surging Today? | Benzinga
UniQure N.V. (NASDAQ:QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington’s disease.
What’s Going On: The latest results, which include up to 24 months of follow-up data from 29 patients across the U.S. and Europe, demonstrated a significant slowing of disease progression. Patients treated ...